Statins inhibit the proliferation and induce cell death of human papilloma virus positive and negative cervical cancer cells

International Journal of Biomedical Science

Volumn 5, Issue 4, 2009, Pages 411-420

  Crescencio, María Elena ^a   Rodríguez, Emma ^a   Páez, Araceli ^a   Masso, Felipe A ^a   Montaño, Luis F ^b   López Marure, Rebeca ^a,c  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Cell cycle; Cell death; Cervical cancer; Human papilloma virus; Mevalonate pathway; Oxidative stress; Proliferation; Statins

Indexed keywords

ATORVASTATIN; FARNESYL DIPHOSPHATE; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; MEVALONIC ACID; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SIMVASTATIN;

ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL ASSAY; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HELA CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; OXIDATIVE STRESS; UTERINE CERVIX CANCER; WART VIRUS;

HUMAN PAPILLOMAVIRUS;

EID: 77953417335     PISSN: 15509702     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Jakobisiak M, Golab J. Potential antitumor effects of statins. Int. J. Oncol. 2003;23: 1055.
2. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425.
3. Alegret M, Silvestre JS. Pleiotropic effects of statins and related pharmacological experimental approaches. Methods Find Exp. Clin. Pharmacol. 2006;28:627.
4. Graaf MR, Richel DJ, van Noorden CJ, GucHeLaar HJ. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat. Rev. 2004;30:609.
5. Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel-Reid S, Freedman MH, Yeger H, Penn LZ. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin. Cancer Res. 2001;7:158.
6. Horiguchi A, Sumitomo M, Asakuma J, Asano T, Asano, T, Hayakawa M. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin. Canc. Res. 2004;10:8648.
7. Gronich N, Drucker L, Shapiro H, Radnay J, Yarkosi S, Lishner M. Symvastatin induces death of multiple myeloma cell lines. J. Inves. Med. 2004;52:335.
8. Janosi J, Sebestyen A, Bocsi J, Barna G, Nagy K, Vályi-Nagy I, Kopper L. Mevastatin-induced apoptosis and growth suppression in U266 myeloma cells. Anticancer Res. 2004;24:1817.
9. Liu ZL, Luo JM, Dong ZR, Wang FX, Zhang XJ, Yang JC, Du XY, Yao L. In vitro effects of mevastatin on the proliferation and apoptosis in human multiple myeloma cell line U266. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2004;12:340.
10. Shibata MA, Ito Y, Morimoto J, Otsuki Y. Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis 2004;25:1887.
11. Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 1991;51:3602.
12. Castelazo G, Molotla D, Basavilvazo MA, Angeles L, Zarate A, Hernandez M. Survival of breast cancer patients treated with inhibitors of the aromatase vs tamoxifen. Ginecol. Obstet. Mex. 2004;72:493.
13. Restrepo HE. Cancer epidemiology and control in women in Latin America and the Caribbean. In: Gender, women and health in the Americas, PAHO, Washington, 1993;pp. 90-103.
14. Robles C, White F, Peruga A. Tendencias de la mortalidad por cáncer de cuello de útero en las Américas. Bol. Oficina Sanit. Panam. 1996;121:478.
15. Monroy GA, Rangel CR, Rocha ZL, Trejo BC, Ramírez GJ, Martínez RD, Weiss-Steider B. Establecimiento de siete estirpes celulares provenientes de biopsias de cérvix normal y con cáncer cérvicouterino y sus diferentes contenidos y localizaciones de desmogleína-1. Rev. Mex. Oncol. 1992;7:69.
16. Kueng W, Silber E, Eppenberg V. Quantification of cells cultured on 96-well plates. Analytical. Biochem. 1989;186:16.
17. Zapata E, Ventura JL, De la Cruz K, Rodríguez E, Damián P, Massó F, Montaño LF, López-Marure R. Dehydroepiandrosterone inhibits the proliferation of HUVEC by enhancing the expression of p53 and p21, restricting the phosphorylation of RB, and is androgen- and estrogen-receptor independent. FEBS J. 2005;272:343.
18. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998;31:1.
19. Rothe G, Valet G. Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2′,7′-dichlorofluorescin. J. Leukoc. Biol. 1990 ;47:440.
20. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganné F, Vannier JP, Soria J, Soria C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001;22:1139.
21. Duncan RE, Lau D, El-Sohemy A, Archer MC. Geraniol and beta-ion-one inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity. Biochem. Pharmacol. 2004;68:1739.
22. Gauthaman K, Richards M, Wong J, Bongso A. Comparative evaluation of the effects of statins on human stem and cancer cells in vitro. Reprod. Biomed. Online 2007;15:566.
23. Sánchez CA, Rodríguez E, Varela E, Zapata E, Páez A, Masso FA, Montaño LF, López-Marure R. Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress. Cancer. Invest. 2008;26:698.
24. Kotamraju S, Williams CL, Kalyanaraman B. Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Cancer Res. 2007;67: 7386.
25. Sivaprasad U, Abbas T, Dutta A. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol. Cancer Ther. 2006;5:2310.
26. Hwang SG, Lee D, Kim J, Seo T, Choe J. Human papillomavirus type 16 E7 binds to E2F1 and activates E2F1-driven transcription in a retinoblastoma protein-independent manner. J. Biol. Chem. 2002;277:2923.
27. Mantovani F, Banks L. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines. Oncogene 1999;18:3309.
28. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001;92:1160.
29. Serajuddin AT, Ranadive SA, Mahoney EM. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J. Pharm. Sci. 1991;80:830.
30. Cohen LH, van Vliet A, Roodenburg L, Jansen LM, Griffioen M. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase. Biochem. Pharmacol. 1993;45:2203.
31. Serajuddin AT, Ranadive SA, Mahoney EM. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J. Pharm. Sci. 1991;80:830.
32. Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ, Kamel-Reid S. Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia 2002;4:337.
33. Cafforio P, Dammacco F, Gernone A, Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 2005;26:883.
34. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425.
35. Wang W, Macaulay RJ. Mevalonate prevents lovastatin-induced apoptosis in medulloblastoma cell lines. Can. J. Neurol. Sci. 1999;26:305.
36. Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD, Penn LZ. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 2001;15:1398.
37. Chapman-Shimshoni D, Yuklea M, Radnay J, Shapiro H, Lishner M. Smvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp. Hematol. 2003;31:779.
38. Kotamraju S, Williams CL, Kalyanaraman B. Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Cancer Res. 2007;67:7386.
39. Ahn KS, Sethi G, Aggarwal BB. Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kappaB pathway. Biochem. Pharmacol. 2008;75:907.
40. Ahn KS, Sethi G, Aggarwal BB. Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1. J. Immunol. 2007;178:2507.
41. Kulbacka J, Saczko J, Chwiłkowska A. Oxidative stress in cells damage processes Pol. Merkur. Lekarski. 2009; 27:44.
42. Laezza C, Fiorentino L, Pisanti S, Gazzerro P, Caraglia M, Portella G, Vitale M, Bifulco M. Lovastatin induces apoptosis of k-ras-transformed thyroid cells via inhibition of ras farnesylation and by modulating redox state. J. Mol. Med. 2008; 86:1341.Cancer Invest. 2008; 26:698.